Weekly Endocrinology Research Analysis
This week’s endocrinology literature highlights mechanistic advances that directly affect diagnosis and potential therapies. A multi-modal reclassification of the INS R6C variant establishes it as a recessive cause of monogenic diabetes, altering genetic counseling and variant interpretation frameworks. Translational work links diet-driven exosomal miR-17-3p to idiopathic short stature and demonstrates a corrective exosome-based strategy in preclinical models. Immuno-mechanistic data identify ga
Summary
This week’s endocrinology literature highlights mechanistic advances that directly affect diagnosis and potential therapies. A multi-modal reclassification of the INS R6C variant establishes it as a recessive cause of monogenic diabetes, altering genetic counseling and variant interpretation frameworks. Translational work links diet-driven exosomal miR-17-3p to idiopathic short stature and demonstrates a corrective exosome-based strategy in preclinical models. Immuno-mechanistic data identify galectin-3 as a suppressor of regulatory T cells in type 1 diabetes, with inhibitor/knockout studies suggesting a tractable therapeutic target.
Selected Articles
1. A new form of diabetes caused by INS mutations defined by zygosity, stem cell and population data.
Integrating population genetics, patient iPSC-derived β-cell modeling, and in vivo grafts, the study demonstrates that INS p.Arg6Cys (R6C) is a recessive loss-of-function variant: homozygotes develop early insulin-requiring diabetes with ER translocation defects, while heterozygotes generally lack enriched diabetes risk. Transcriptomics reveal attenuated translation/ER signatures and homozygous β cells respond poorly to GLP-1RA.
Impact: Reclassifies a widely cited INS variant using complementary population and mechanistic data, resolving ambiguity and demonstrating a template for multi-modal variant interpretation in monogenic diabetes.
Clinical Implications: Genetic counseling and cascade testing should consider recessive inheritance for R6C; heterozygous carriers may not need intensified diabetes surveillance. Expect potential poor GLP-1RA response in affected homozygotes, influencing therapeutic planning.
Key Findings
- Homozygous INS R6C causes early-onset insulin-treated diabetes with β-cell ER translocation defects; heterozygotes lack population-level diabetes enrichment.
- iPSC-derived homozygous β cells accumulate preproinsulin and have reduced insulin content/secretion; transcriptomics show attenuated translation/ER pathway signatures.
- In vivo β-cell grafts from homozygotes recapitulate insulin deficiency and poor GLP-1RA responsiveness.
2. Capsaicin diet drives gut inflammation and exosomal miR-17-3p elevation in idiopathic short stature.
This translational study links a capsaicin-rich diet to idiopathic short stature (ISS) via elevated exosomal miR-17-3p that suppresses ZNF148/SOS1 signaling and impairs chondrocyte proliferation. A rat model recapitulated ISS-like features with gut inflammation and raised exosomal miR-17-3p despite normal GH/IGF-1. Engineered anti–miR-17-3p exosomes combined with localized growth hormone restored growth plate function in preclinical models.
Impact: Uncovers a diet–exosome–growth axis mediated by a specific miRNA and demonstrates a corrective preclinical strategy, potentially transforming diagnosis and treatment approaches for ISS in high-capsaicin populations.
Clinical Implications: Motivates assessing dietary capsaicin exposure and validating exosomal miR-17-3p as a biomarker for ISS risk stratification; supports early-phase trials of miR-17-3p–targeted therapies combined with GH in selected populations.
Key Findings
- Plasma exosomes from ISS children contain elevated hsa-miR-17-3p which impairs chondrocyte proliferation via ZNF148/SOS1 suppression.
- Capsaicin-rich diet in rats induces gut inflammation and increases intestinal/plasma exosomal miR-17-3p without altering GH/IGF-1, recapitulating ISS features.
- Engineered anti–miR-17-3p exosomes plus local GH restored growth plate function in preclinical models; ISS children’s feces showed similar miR-17-3p/inflammatory signatures.
3. Galectin-3 exacerbates autoimmune diabetes by limiting regulatory T cell differentiation and function.
The study finds elevated circulating galectin-3 in type 1 diabetes patients and their first-degree relatives, mainly produced by monocytes/macrophages. Pharmacologic inhibition (TD139) and genetic knockout relieved galectin-3–mediated suppression of regulatory T cells, identifying a mechanistic, drug-targetable axis for immune modulation in T1D.
Impact: Links a measurable circulating lectin to impaired Treg biology in human T1D and demonstrates reversibility with an existing inhibitor, enabling rapid translational exploration for prevention or disease modification.
Clinical Implications: Galectin-3 could be developed as a biomarker to identify at-risk relatives and as a therapeutic target; clinical trials of galectin-3 inhibition (e.g., inhaled or systemic TD139-like agents) in early or at-risk T1D populations are warranted.
Key Findings
- Serum galectin-3 is elevated in T1D patients and first-degree relatives compared with controls.
- Monocytes/macrophages are the primary source of circulating galectin-3.
- Pharmacologic inhibition (TD139) and galectin-3 knockout attenuate galectin-3–mediated suppression of regulatory T cells.